[{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Sanders Morris Harris","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Series A Financing","leadProduct":"Dapansutrile","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Olatec Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Olatec Therapeutics \/ Sanders Morris Harris","highestDevelopmentStatusID":"9","companyTruncated":"Olatec Therapeutics \/ Sanders Morris Harris"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ABP-671","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ABP-671","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Series D Financing","leadProduct":"ABP-671","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ABP-671","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable"}]